samedan logo
 
 
spacer
home > epc > Winter 2008
PUBLICATIONS

European Pharmaceutical Contractor

epc
Winter 2008
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EPC provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of pharmaceuticals, take a look below at the range of articles featured in the current issue of EPC.
   
Text
PDF
bullet
Marketplace & Business
Recognising the high costs of clinical research and the demand for rapid advancements, John Paul at Frost & Sullivan examines the benefits of outsourcing strategies for organisational success, in As the CRO Flies  
view
download pdf
In A Passage to India, IndiPharm’s Edward J Brennan recommends cutting costs and increasing productivity by relocating clinical trials to the latest pharmaceutical frontier  
view
download pdf
Nacho Mbeliachi at Healthcare Project Management asserts that the business expansion rates of CROs will have a positive effect on the future of the medical writing agencies that are Gunning for Growth  
view
download pdf
Adding contract design services is not a short-term strategy but a Design for Life, concludes Eric Resnick at The Tech Group, examining its cost and capability advantages for contract manufacturers  
view
download pdf
Current trends suggest research outsourcing is set for a dramatic increase in the years ahead. In Asian Allstars, TS Jaishankar of Quest Life Sciences examines the pros and cons of expanding business into the Asian region  
view
download pdf
bullet
Clinical Development
Rapid advancements in regulations have resulted in a new Mexican Twist within the pharmaceutical industry. Christopher Davies of Pharmalink Consulting assesses dramatic improvements for the leader of the Latin American market  
view
download pdf
In the light of adverse cardiac drug reactions, Jean Barbey of Medifacts International demonstrates, in Skipping a Beat, the importance of accurately measuring QT intervals during clinical research  
view
download pdf
Amy Furlong at eResearchTechnology, Inc highlights the vital characteristics at the heart of an effective ECG digital data management system, in Quality to the Core  
view
download pdf
The future of clinical studies may lie in the growth potential of adaptive designs. Analysing the statistical design procedures of the planning stage,Thorsten Reineke at MSOURCE considers sample sizes and The Laws of Adaptation  
view
download pdf
Collaborative efforts between sectors of the pharmaceutical industry are Building Foundations for innovative technical documents. Jeffery J Bowden and Frank Dunn at Biomedical Systems evaluate the future of medical imagining standardisation  
view
download pdf
bullet
Legal & Regulatory
Discussing novel responses to new regulatory requirements, Jim Nichols at Thomson Scientific maintains that the core of new integration strategies should be Connecting the Dots of isolated data points and refining the management of regulatory affairs  
view
download pdf
With clinical outsourcing gathering momentum in the globalised drugs arena, Sabine Richter of PRA International emphasises the requirements of an effective pharmacovigilance service and presents the Best Practices to Ensure Success  
view
download pdf
In a bid to clarify who will be first to cross The Finnish Line, Hanna Paloheimo at Borenius & Kemppinen analyses Finland’s complex inventions legislation  
view
download pdf
The media reports tort claims resulting from adverse pharmaceutical effects on both sides of the Atlantic, but Darren Smith and Heather Ritch at Reed Smith Richards Butler LLP compare A World of Difference between litigation results in the US and the UK  
view
download pdf
Examining The New Penalties Regulation for infringements, Elisabethann Wright and Susan Jane Clements at Hogan & Hartson reveal the complex debate surrounding breaches of marketing authorisation  
view
download pdf
Dr Jenny Gebhardt of BPI Service GmbH and Gloria Cenni of Bassilichi Spa describe the application of standard validation processes to vital pharmacovigilance software, in Joining Forces  
view
download pdf
bullet
Data Management & IT Solutions
Gaining Access to new medicines in trials is a vital concern for critical patients. Angus G Cameron of BR Pharma Limited investigates the life-enhancing benefits of compassionate use and named patient programmes  
view
download pdf
In Moving Beyond Recruitment Barriers, Julie Ross of Essential Group, Inc considers the enrichment of enrolment programmes through empowering potential trial subjects to seek participation in clinical studies  
view
download pdf
As offshoring becomes increasingly the norm in clinical trials, companies are turning to the ample medical resources of the former USSR. Vladimir V Novakovskiy at Congenix, LLC outlines the region’s study management potential in From Russia with Success  
view
download pdf
Wade Wirta of Perceptive Informatics claims that IVRS constitutes an important tool for the clinical trial process in the competitive drive to reduce drug supply costs and improve risk management, in Voicing Demands  
view
download pdf
bullet
Logistics
In Keeping Cool, Geraint Thomas at Laminar Medica emphasises the crucial importance of adequate control measures in the transport of temperature-sensitive materials, and its implications for clinical trial success  
view
download pdf
In an industry constantly demanding condition-critical shipment of dangerous goods, proper packaging is essential. In his review of specifications and label changes, Jay Johnson at Inmark opines that Handling Hazards doesn’t have to be a risky business  
view
download pdf
bullet
DRUG DISCOVERY, DELIVERY & THERAPEUTICS
In A Marriage of Convenience, Dr Andrew Reason of M-Scan Limited and Stéphane Canarelli and Dr Bernard Ludwig of M-Scan SA examine the development of molecular peptides for therapeutic use and recommend the effective union of chromatography and tandem-mass spectrometry  
view
download pdf
Fixing Form and Formulation for Phase I is essential in determining the suitability of new drug compounds. Paul Fagan of Aptuit offers strategies that ensure poorly soluble candidates reach early clinical stages  
view
download pdf
The growth of international collaboration in large-scale clinical research networks demands the data-sharing capabilities of Image Integration solutions, claim Dr Robert Modre-Osprian and Dr Günter Schreier at Austrian Research Centers GmbH  
view
download pdf
bullet
Clinical Laboratories
Peter Reynolds of Image Solutions, Inc considers the dynamic adoption of eCTD processes to improve productivity, in Opening the Door to Change  
view
download pdf
Generic LIMS systems need a boost to adapt to the laboratory environment, claims Jørn Christensen at LabWare – There’s no LIMit to the additional function of new-generation LIMS  
view
download pdf
   
spacer
Edited by
Dr Graham Hughes,
Consultant in
Pharmaceutical
Development
Published quarterly in
February, May,
August and November

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

News and Press Releases

PFIZER PRESENTS OVERALL SURVIVAL DATA FOR SUTENT™ VERSUS INTERFERON-ALFA

Chicago, 31 May 2008- Results from a landmark study have shown that sunitinib (SUTENT™) has demonstrated overall survival greater than two years in patients with metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer.  This is the first time overall survival data representing more than two years has been achieved in the first line setting of mRCC, which is clinically meaningful and reflective of major advances in the treatment of kidney cancer. 
More info >>


__________________________


__________________________


__________________________


__________________________

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement